---
$id: https://graph.org.ai/products/commodity/51112004
$type: Product
source: UNSPSC
code: "51112004"
title: "Gefitinib"
class: "51112000"
classTitle: "Tyrosine kinase inhibitors"
family: "51110000"
familyTitle: "Antineoplastic agents"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Gefitinib

**UNSPSC Code**: 51112004
**Class**: [Tyrosine kinase inhibitors](Tyrosine kinase inhibitors.mdx)
**Family**: [Antineoplastic agents](../Antineoplastic agents.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a tyrosine kinase inhibitor with the molecular formula C22H24ClFN4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S65743JHBS, chemically known as 4-quinazolinamine, n-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)- but generally known as gefitinib, which bears US NIH Compound Identifier 123631. European Medicines Agency schedules Gefitinib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20637. The term GEFITINIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16., No. 1.2002, List 47). World Health Organization schedules gefitinib in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule gefitinib under HS 29349990 and SITC 51579. As of Q4 2014, GEFITINIB remains the US FDA Preferred Term for this commodity. Gefitinib bears US NLM identifiers UMLS ID C1122962 and NCI Concept Code C1855. SMILES: CLC1CC(NC2NCNC3C2CC(OCCCN2CCOCC2)C(OC)C3)CCC1F.

